Evidence map›Paper›PMID 29116467›Full record

Trial reportBreast cancer research and treatment2018

Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial.

Catherine C Going, Ludmila Alexandrova, Kenneth Lau, Christine Y Yeh, David Feldman, Sharon J Pitteri

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. 27-Hydroxycholesterol, an Endogenous SERM, and Risk of Fracture in Postmenopausal Women: A Nested Case-Cohort Study in the Women's Health Initiative.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019
    Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. VDMolecular biology reports · 2020
    Article
  9. Article
  10. Consensus statement from 2Reviews in endocrine & metabolic disorders · 2020
    Article
  11. Intratumoral Sterol-27-Hydroxylase (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Catherine C GoingDepartment of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, 3155 Porter Drive, MC5483, Palo Alto, CA, 94304, USA.ORCID http://orcid.org/0000-0003-0577-8498
Ludmila AlexandrovaVincent Coates Foundation Mass Spectrometry Laboratory, Stanford University, Stanford, CA, 94305, USA.
Kenneth LauDepartment of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, 3155 Porter Drive, MC5483, Palo Alto, CA, 94304, USA.
Christine Y YehDepartment of Biomedical Informatics, Stanford University School of Medicine, Stanford, CA, 93405, USA.
David FeldmanDepartment of Medicine - Endocrinology, Stanford University School of Medicine, Stanford, CA, 93405, USA.
Sharon J PitteriDepartment of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, 3155 Porter Drive, MC5483, Palo Alto, CA, 94304, USA. spitteri@stanford.edu.
Stanford University · USStanford Medicine · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
NCI NIH HHS P30 CA124435
6 · The paper itself

Abstract

purpose27-hydroxycholesterol (27HC), an endogenous selective estrogen receptor modulator (SERM), drives the growth of estrogen receptor-positive (ER+) breast cancer. 1,25-dihydroxyvitamin D (1,25(OH)

methods27HC, 25-hydroxyvitamin D (25OHD), and 1,25(OH)

resultsA significant increase (p = 4.3E-5) in 25OHD and a decrease (p = 1.7E-1) in 27HC was observed in high-dose versus low-dose vitamin D subjects. Excluding two statistical outliers, 25OHD and 27HC levels were inversely correlated (p = 7.0E-3).

conclusionsVitamin D supplementation can decrease circulating 27HC of breast cancer patients, likely by CYP27A1 inhibition. This suggests a new and additional modality by which vitamin D can inhibit ER+ breast cancer growth, though a larger study is needed for verification.

Indexed as

25-Hydroxyvitamin D3 1-alpha-HydroxylaseBiopsyBreast NeoplasmsCell Line, TumorCholestanetriol 26-MonooxygenaseDietary SupplementsFemaleGene Expression Regulation, NeoplasticHumansHydroxycholesterolsReceptors, EstrogenSelective Estrogen Receptor ModulatorsVitamin D25-Hydroxyvitamin D3 1-alpha-Hydroxylase27-hydroxycholesterolCholestanetriol 26-MonooxygenaseCYP27A1 protein, humanCYP27B1 protein, humanHydroxycholesterolsReceptors, EstrogenSelective Estrogen Receptor ModulatorsVitamin D27-hydroxycholesterolCalcitriolCYP27A1ER+ breast cancerVitamin D

Identifiers

PMID29116467
PMCPMC6381934
OpenAlexW2767417542

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.